coli or in Klebsiella spp. (Figure 1). Figure 1 Multi-step selection of resistance in E. coli (A) and Klebsiella spp. (B) at plasma concentration of fluoroquinolones. 1, 5, 10 step: number of passages on antibiotic AZ 628 gradient agar plates. 10 step free: passages on antibiotic free agar plates. Black bars: prulifloxacin; White bars: ciprofloxacin; Dotted bars: levofloxacin. Characterization of acquired resistance Strains of E. coli that were
selected by the multi-step assay and were able to maintain their resistance after 10 passages in antibiotic-free medium, were evaluated for acquired resistance. Among 16 resistant mutants, alterations in both gyrA and parC were found in 12 mutants for ciprofloxacin (n = 5) and prulifloxacin (n = 7), while only Crizotinib price alterations in gyrA were found for levofloxacin. As reported in table 4, the 4 strains resistant to levofloxacin showed changes in Ser83Leu and Asp87Asn; while in ciprofloxacin- and prulifloxacin-resistant mutants, the mutations identified were Ser83Leu in GyrA and Ser80Ile in ParC. The same mutations were
not found in the respective parent strains. Table 4 Amino acid changes encoded by mutations in gyrA, gyrB, parC, and parE in E. coli Replacement in QRDR Drug GyrA GyrB ParC ParE LVX (n = 4) Ser83Leu (4) Asp87Asn (4) – - – CIP (n = 5) Ser83Leu (5) – Ser80Ile (5) – PRU (n = 7) Ser83Leu (7) – Ser80Ile (7) – Discussion Wild-type E. coli and K. pneumoniae clinical isolates are susceptible to quinolones, but resistance to these agents in Gram-negative bacteria has increased in recent years, probably caused by excessive and inappropriate use of Bupivacaine these drugs [18]. Particularly, due to under-dosing and mono-therapy against moderately susceptible pathogens, FQ resistance has developed among common pathogens, like E. coli and Klebsiella spp., mainly conferred by ESBLs and AmpC enzymes [19]. ESBL production has been reported to be two times more common in infected patients who received ciprofloxacin than in those who did not (15% vs
7.4%) [8]. In a study performed over 5 years in Croatia on changes in susceptibility of E. coli from UTI, Moeal et al have shown a statistically significant change in antimicrobial resistance over that period only for ciprofloxacin [20]. This has been hypothesized to be related to the inappropriate use of quinolones for humans as well as in veterinary medicine [21]. Prolonged use (> 20 days) of low dose (250 mg twice a day) of the more potent fluoroquinolones such as ciprofloxacin or levofloxacin, has been shown to be the most significant risk factor for acquisition of resistance [22, 23]. Strategies to counteract bacterial LOXO-101 in vivo resistances include use of the appropriate dosages of these molecules for the correct indication and/or use of synergistic combinations, particularly in the more complicated infections.